Gain Therapeutics Inc Market Cap ($49.05 Million)
Market Cap & Net Worth: Gain Therapeutics Inc (GANX)
Gain Therapeutics Inc market cap. Gain Therapeutics Inc (NASDAQ:GANX) has a market capitalization of $49.05 Million ($49.05 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21783 globally and #4868 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gain Therapeutics Inc's stock price $1.15 by its total outstanding shares 42654038 (42.65 Million). Also see Gain Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Gain Therapeutics Inc Market Cap History (2021–2026)
Gain Therapeutics Inc market cap history from 2021 to 2026. Data shows change from $231.61 Million to $49.05 Million (-33.24% CAGR). Check latest Gain Therapeutics Inc stock price today for real-time trading data and today's change.
Index Memberships
Gain Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #618 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2064 of 3165 |
Weight: Gain Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Gain Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gain Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Gain Therapeutics Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2523.84x
Gain Therapeutics Inc's market cap is 2523.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $231.61 Million | $133.93K | -$13.89 Million | 1729.37x | N/A |
| 2022 | $133.51 Million | $132.64K | -$17.59 Million | 1006.54x | N/A |
| 2023 | $139.27 Million | $55.18K | -$22.27 Million | 2523.84x | N/A |
Competitor Companies of GANX by Market Capitalization
Companies near Gain Therapeutics Inc in the global market cap rankings as of November 4, 2026. Also see GANX total assets for a full breakdown of the balance sheet.
Key companies related to Gain Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Gain Therapeutics Inc (2021–2026)
Market capitalization of Gain Therapeutics Inc from 2021 to today. Between 2021 and today, Gain Therapeutics Inc's market cap moved from $231.61 Million to $ 49.05 Million, with a yearly change of -33.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $49.05 Million | -64.29% |
| 2025 | $137.35 Million | +49.07% |
| 2024 | $92.13 Million | -33.84% |
| 2023 | $139.27 Million | +4.31% |
| 2022 | $133.51 Million | -42.36% |
| 2021 | $231.61 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Gain Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.05 Million USD |
| MoneyControl | $49.05 Million USD |
| MarketWatch | $49.05 Million USD |
| marketcap.company | $49.05 Million USD |
| Reuters | $49.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and t… Read more